Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Megan Collett

Nurse Practitioner Lexington, KY Nurse Practitioner

NPI 1134580145 CMS profile 10520217

3470 Blazer Pkwy Ste 150, Lexington, KY 40509

Open in the dashboard

General payments

$13,402

640 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Megan Collett of Lexington, KY is reported in the CMS Open Payments database as having received $13,402 across 640 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,542 152
2024 General $5,498 153
2023 General $1,992 113
2022 General $2,317 158
2021 General $1,053 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Collett
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Megan Collett were reported at $2,542. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Megan Collett Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,053 $135 $40–$426 $132
2022 $2,317 $152 $48–$470 $149
2023 $1,992 $166 $54–$529 $160
2024 $5,498 $173 $55–$556 $164
2025 $2,542 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. EMD Serono, Inc. $3,574 32 payments
  2. AbbVie, Inc. $2,534 209 payments
  3. Alexion Pharmaceuticals, Inc. $694 22 payments
  4. Biogen, Inc. $519 29 payments
  5. Pfizer Inc. $480 50 payments
  6. Novartis Pharmaceuticals Corporation $449 36 payments
  7. Lilly USA, LLC $401 26 payments
  8. Janssen Pharmaceuticals, Inc $372 18 payments
  9. Teva Pharmaceuticals USA, Inc. $278 9 payments
  10. Eisai Inc. $266 12 payments
  11. Other $3,835 197 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,261 629 payments
  2. Consulting Fee $2,585 1 payment
  3. Education $556 10 payments
Products named General payments · program years 2021–2025
  1. Mavenclad $2,902 4 payments
  2. UBRELVY $1,057 87 payments
  3. QULIPTA $954 78 payments
  4. BOTOX Botox Therapeutic $662 55 payments
  5. ULTOMIRIS $464 18 payments
  6. NURTEC ODT $421 47 payments
  7. ZAVZPRET $408 46 payments
  8. TYSABRI $379 22 payments
  9. BOTOX Neuroscience $279 24 payments
  10. Ponvory $275 16 payments
  11. Other $5,835 325 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

4,137

Median for Nurse Practitioner: 389

Drug cost

$1,111,569

Median for Nurse Practitioner: $21,885

Branded share of claims

29.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 150 $171,627
Nuplazid Pimavanserin Tartrate Brand 21 $106,363
Ingrezza Valbenazine Tosylate Brand 12 $101,158
Avonex Pen (4 Pack) Interferon Beta-1a Brand 12 $94,850
Bafiertam Monomethyl Fumarate Brand 11 $74,051
Topiramate Er Topiramate Brand 65 $62,713
Qulipta Atogepant Brand 48 $61,985
Emgality Pen Galcanezumab-Gnlm Brand 73 $59,647
Aimovig Autoinjector Erenumab-Aooe Brand 69 $57,807
Nurtec Odt Rimegepant Sulfate Brand 51 $50,508

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$50,599

Of which drugs: $33,202

Medicare patients

163

Average age 69

Services billed

7,116

103 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 58%
Depression 40%
Diabetes 34%
Ischemic heart disease 31%
Chronic kidney disease 25%
Alzheimer's or dementia 23%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 11 6,200 $30,731

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Mavenclad
  • EMD Serono, Inc. $2,706
$2,706 — —
QULIPTA
  • AbbVie, Inc. $318
$318 48 —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $220
$220 — —
BOTOX
  • AbbVie, Inc. $196
$196 — 6,200
Rystiggo
  • UCB, Inc. $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

640 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record